After-Hours Movers 11/08: (SAEX) (ARTX) (GMED) Higher; (TRIP) (MPSX) (JAZZ) Lower (more...)

November 8, 2016 6:05 PM EST
Get Alerts SAEX Hot Sheet
Trade SAEX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Today's After-Hours Movers

SAExploration Holdings, Inc. (NASDAQ: SAEX) 21.8% HIGHER; announced a new project award for seismic data acquisition services valued at approximately $35 million.

TripAdvisor (NASDAQ: TRIP) 13.3% LOWER; reported Q3 EPS of $0.53, in-line with the analyst estimate of $0.53. Revenue for the quarter came in at $421 million versus the consensus estimate of $436.31 million.

Arotech Corp. (NASDAQ: ARTX) 12.8% HIGHER; reported Q3 EPS of $0.02, $0.03 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $24.3 million versus the consensus estimate of $24 million.

Globus Medical (NYSE: GMED) 10.2% LOWER; reported Q3 EPS of $0.29, in-line with the analyst estimate of $0.29. Revenue for the quarter came in at $135.7 million versus the consensus estimate of $139.25 million. GUIDANCE: Globus Medical sees FY2016 EPS of $1.20, versus the consensus of $1.20. Globus Medical sees FY2016 revenue of $560 million, versus the consensus of $574.79 million.

Multi Packaging Solutions (NYSE: MPSX) 8.1% LOWER; reported Q1 EPS of $0.17, $0.08 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $407.8 million versus the consensus estimate of $425.27 million.

Hertz Global Holdings (NYSE: HTZ) 3.5% HIGHER; Carl Icahn disclosed a 33.77%, or 28,019,038 share, stake in the company. This is up 116.55% from the 12,938,596 shares held at the end of the latest quarter ending September 30, 2016. All the new shares were purchased today.

ILG (NASDAQ: ILG) 3.2% HIGHER; reported Q3 EPS of $0.39, $0.13 better than the analyst estimate of $0.26. Revenue for the quarter came in at $418 million versus the consensus estimate of $387 million.

ViaSat (NASDAQ: VSAT) 2.9% HIGHER; reported Q2 EPS of $0.40, $0.13 better than the analyst estimate of $0.27. Revenue for the quarter came in at $399.2 million versus the consensus estimate of $378.83 million.

Jazz Pharmaceuticals (NASDAQ: JAZZ) 2% LOWER; reported Q3 EPS of $2.57, $0.04 worse than the analyst estimate of $2.61. Revenue for the quarter came in at $374 million versus the consensus estimate of $389.23 million. GUIDANCE: Jazz Pharmaceuticals sees FY2016 EPS of $9.90-$10.30, versus the consensus of $10.06. Jazz Pharmaceuticals sees FY2016 revenue of $1.485-1.53 billion, versus the consensus of $1.51 billion.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Carl Icahn, After-Hours Movers, Definitive Agreement

Add Your Comment